Related Experiment Videos
Hyperhomocysteinaemia in patients with peripheral arterial occlusive disease
1Department of Surgery, Free University Hospital, Amsterdam, The Netherlands. sc.dejong@azvu.nl
Insights
High homocysteine levels are linked to atherosclerosis and premature vascular disease. Treatment with vitamins may help, but more research is needed to confirm its protective effects in peripheral arterial occlusive disease (PAD).
Area of Science:
- Cardiovascular Medicine
- Vascular Biology
- Nutritional Science
Background:
- Cardiovascular disease remains a leading cause of death globally.
- Elevated total homocysteine levels are increasingly recognized as a significant risk factor for atherosclerosis and premature vascular disease.
- Hyperhomocysteinaemia (HHC) affects a substantial percentage (25-32%) of patients with premature peripheral arterial occlusive disease (PAD).
Purpose of the Study:
- To investigate the association between high total homocysteine concentrations and the progression of atherosclerosis.
- To evaluate the role of HHC in the development and severity of premature peripheral arterial occlusive disease (PAD).
- To explore the potential benefits of treating HHC with vitamin B6 and folic acid in patients with PAD.
Main Methods:
- Analysis of retrospective and prospective studies on patients with PAD.
- Evaluation of clinical course and disease progression in relation to homocysteine levels.
- Assessment of associations between HHC, atherosclerosis severity, and mortality rates.
Main Results:
- Significant associations found between high total homocysteine concentrations and increased atherosclerosis severity.
- High homocysteine levels correlated with more rapid disease progression and higher mortality rates in PAD patients.
- HHC is a prevalent condition in patients experiencing premature PAD.
Conclusions:
- High homocysteine levels are a relevant risk factor for atherosclerosis and premature PAD.
- While vitamin B6 and folic acid show potential for treating HHC, further prospective randomized clinical trials are essential.
- Urgent research is needed to definitively establish the role of HHC and its treatment in managing premature PAD.
Abstract:
In the Western world, cardiovascular disease is still the most common cause of death. Over the past decade it has become clear that apart from common risk factors, high concentrations of total homocysteine are relavant to the process of atherosclerosis, especially in the development of premature vascular disease. Hyperhomocysteinaemia (HHC) can be found in 25-32% of the patients with premature peripheral arterial occlusive disease (PAD). Retrospective and prospective studies, evaluating the clinical course of patients with PAD, showed significant associations between high concentrations of total homocysteine and the severity of atherosclerosis and with a more rapid disease progression and mortality rates. HHC can be treated with vitamin B6 and folic acid. Although there may be indications that there is a protective effect of treatment, prospective randomized clinical trials are urgently needed to unravel the role of HHC and its treatment in patients with premature PAD.